International journal of radiation oncology, biology, physicsAug 22, 2009

Temozolomide increases radiation sensitivity only in some brain tumors with specific DNA repair changes

Circadian Biology Weekly Brief ↗PubMed ↗DOI ↗

Updated Mar 27, 2026

Abstract

The median survival ratio for patients with MGMT methylated tumors treated with concurrent temozolomide and radiation therapy was 5.7, compared to 2.3 for those with unmethylated tumors.

Treatment with temozolomide (TMZ) and radiation therapy (RT) significantly improved survival in MGMT methylated glioblastoma tumors compared to unmethylated tumors.
MGMT methylation status and p53 mutation status were significantly associated with treatment response.
Only a subset (5 of 11) of MGMT methylated tumors showed substantial additional survival benefit from concurrent therapy compared to TMZ alone.
Sequential treatment of RT followed by TMZ was significantly less effective than concurrent treatment or TMZ followed by RT.

Simplified

PURPOSE: Concurrent temozolomide (TMZ) and radiation therapy (RT) followed by adjuvant TMZ is standard treatment for patients with glioblastoma multiforme (GBM), although the relative contribution of concurrent versus adjuvant TMZ is unknown. In this study, the efficacy of TMZ/RT was tested with a panel of 20 primary GBM xenografts.

METHODS AND MATERIALS: Mice with intracranial xenografts were treated with TMZ, RT, TMZ/RT, or placebo. Survival ratio for a given treatment/line was defined as the ratio of median survival for treatment vs. placebo.

RESULTS: The median survival ratio was significantly higher for O6-methylguanine-DNA methyltransferase (MGMT) methylated tumors versus unmethylated tumors following treatment with TMZ (median survival ratio, 3.6 vs. 1.5, respectively; p = 0.008) or TMZ/RT (5.7 vs. 2.3, respectively; p = 0.001) but not RT alone (1.7 vs. 1.6; p = 0.47). In an analysis of variance, MGMT methylation status and p53 mutation status were significantly associated with treatment response. When we analyzed the additional survival benefit conferred specifically by combined therapy, only a subset (5 of 11) of MGMT methylated tumors derived substantial additional benefit from combined therapy, while none of the MGMT unmethylated tumors did. Consistent with a true radiosensitizing effect of TMZ, sequential treatment in which RT (week 1) was followed by TMZ (week 2) proved significantly less effective than TMZ followed by RT or concurrent TMZ/RT (survival ratios of 4.0, 9.6 and 12.9, respectively; p < 0.0001).

CONCLUSIONS: Concurrent treatment with TMZ and RT provides significant survival benefit only in a subset of MGMT methylated tumors and provides superior antitumor activity relative to sequential administration of RT and TMZ.

Full Text

Full text is available at the source.

View Full Text ↗

Temozolomide increases radiation sensitivity only in some brain tumors with specific DNA repair changes

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief